Karim FIZAZI, MD
Gustave Roussy, Cancer Campus, Grand Paris · Gustave Roussy, Villejuif · Gustave Roussy Cancer Campus, France
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Karim FIZAZI, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:40 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06625970 · Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseUNICANCER · recruiting · High Risk Prostate Carcinoma, Prostate Cancer · study chair
- Ph3NCT06496581 · Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)UNICANCER · recruiting · Prostate Cancer Metastatic · study chair
- Ph3NCT05874063 · Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell TumorsGustave Roussy, Cancer Campus, Grand Paris · recruiting · Germ Cell Tumor · principal investigator
- Ph3NCT04916613 · ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)UNICANCER · recruiting · Prostate Cancer Metastatic · principal investigator
- Ph2NCT03314324 · A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerGustave Roussy, Cancer Campus, Grand Paris · completed · Metastatic Castrate-resistant Prostate (CRPC) Cancer · study chair
- Ph2NCT02115165 · A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell TumorsGustave Roussy, Cancer Campus, Grand Paris · completed · Non-seminomatous Germ-cell Tumors · study chair
- Ph3NCT02044354 · Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate CancerGustave Roussy, Cancer Campus, Grand Paris · completed · Metastatic Castration-resistant Prostate Cancer · study chair
- Ph1NCT01784757 · Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate CancerOrion Corporation, Orion Pharma · completed · Prostate Cancer · principal investigator
- Ph3NCT01540058 · Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUPGustave Roussy, Cancer Campus, Grand Paris · completed · Neoplasms, Unknown Primary · principal investigator
- Ph3NCT00617669 · A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate CancerAstraZeneca · completed · Prostate Cancer · principal investigator
- Ph3NCT00104676 · Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell TumorsUNICANCER · completed · Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor · study chair
- Ph3NCT00055731 · Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of RelapseUNICANCER · completed · Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.